REG - IXICO plc - New Contract Win

IXICOAnnouncement

21/04/2022 07:00

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20220421:nRSU8126Ia&default-theme=true

RNS Number : 8126I  IXICO plc  21 April 2022

21 April 2022

IXICO plc

("IXICO" or the "Company")

 

Contract award with a new client for a Huntington's Disease ('HD') trial worth
circa £800,000

 

IXICO plc (AIM: IXI), the neuroimaging Contract Research Organisation (CRO)
delivering advanced AI analytical insights in neuroscience, is pleased to
announce it has been selected by a new client to support its global
prospective observational study to assess participants for the early detection
of HD.  HD is a rare, inherited disease that causes the progressive breakdown
of nerve cells in the brain affecting movement, mood and thinking abilities.

 

The new client is a biotech company specialized in gene therapy for
neurodegenerative and other genetic diseases. IXICO will provide a range of
its imaging CRO and advanced analytics services across approximately 2.5
years.

 

Having combined AI imaging biomarker analysis across many HD trials, together
with centralised CRO services, IXICO is continuously enhancing its validated
disease-optimised advanced analytics technology for this indication.  This
new contract follows our recent presentation on our new deep learning-based
platform, IXIQ.Ai, at the Annual HD Therapeutics Conference in Palm Springs, a
technology which IXICO will be applying to this trial.  This, together with
the ability to deliver its services through our proprietary TrialTracker
imaging data management platform, makes IXICO the clear partner of choice for
this study.

 

Giulio Cerroni, Chief Executive Officer of IXICO, commented: "With no current
cure for Huntington's, nor interventions that slow disease progression, HD is
a devastating rare neurological condition with significant unmet medical
needs. We are delighted to further extend our client base and support
identifying new insights into this challenging rare neurodegenerative disease.
We are committed to ensuring that our validated machine learning AI data
analytics, combined with the quality assurance of our TrialTracker platform,
enable clients to unlock new insights into disease progression and drug
development."

 

For further information please contact:

 

 IXICO plc                                                +44 (0)20 3763 7499
 Giulio Cerroni, Chief Executive Officer

 Grant Nash, Chief Financial Officer

 Cenkos Securities PLC (Nominated adviser and sole broker)                 +44 (0)20 7397 8900
 Giles Balleny / Max Gould (Corporate Finance)
 Michael F Johnson / Tamar Cranford-Smith (Sales)

 

About IXICO | Advanced Analytics | Intelligent Insights.

IXICO is dedicated to delivering insights in neuroscience to help transform
the advancement of investigational therapies for neurological diseases, such
as Huntington's, Parkinson's, Alzheimer's disease and Multiple Sclerosis. The
Company's purpose is to advance medicine and human health by turning data into
clinically meaningful information, providing valuable new insights in
neuroscience by supporting pharmaceutical companies across all phases of CNS
clinical research. IXICO's goal is to be a leading advocate of artificial
intelligence in medical image analysis.

 

IXICO has developed and deployed breakthrough machine learning Ai data
analytics, at scale, through its remote access TrialTracker technology
platform, to improve the return on investment in drug development and reduce
risk and uncertainty in clinical trials for the Company's pharmaceutical
clients.

 

More information is available on www.IXICO.com (http://www.IXICO.com)  and
follow us on Twitter @IXICOnews

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  CNTQBLFLLZLZBBK